Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 9:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: High-risk Smoldering Multiple Myeloma Clear all
Completed Phase 2 Interventional Results available

Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma

NCT01572480
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Revlimid, Dexamethasone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 25, 2026, 9:10 AM EDT
Recruiting Phase 2 Interventional

Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

NCT04776395
View directory record Official record
Conditions
Smoldering Plasma Cell Myeloma
Interventions
Dexamethasone, Iberdomide Hydrochloride, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 25, 2026, 9:10 AM EDT
Terminated Phase 2 Interventional Results available

Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients

NCT02943473
View directory record Official record
Conditions
High Risk Smoldering Multiple Myeloma
Interventions
Ibrutinib
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2020 · Synced Sep 25, 2026, 9:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

NCT00112827
View directory record Official record
Conditions
Refractory Multiple Myeloma, Smoldering Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
total marrow irradiation, melphalan, peripheral blood stem cell transplantation, filgrastim, fluorescence in situ hybridization, cytogenetic analysis, cyclophosphamide, autologous-autologous tandem hematopoietic stem cell transplantation, lenalidomide
Radiation · Drug · Procedure + 2 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Up to 70 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2019
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Sep 25, 2026, 9:10 AM EDT
Recruiting Phase 2 Interventional

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

NCT06140524
View directory record Official record
Conditions
Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM)
Interventions
Linvoseltamab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
7
States / cities
Baltimore, Maryland • Boston, Massachusetts • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 25, 2026, 9:10 AM EDT
Active, not recruiting Phase 2 Interventional

Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)

NCT02960555
View directory record Official record
Conditions
Smoldering Plasma Cell Myeloma
Interventions
Isatuximab, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
3
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 25, 2026, 9:10 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

NCT03236428
View directory record Official record
Conditions
Monoclonal Gammopathy, Smoldering Multiple Myeloma
Interventions
Daratumumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
6
States / cities
Monterey, California • Denver, Colorado • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 25, 2026, 9:10 AM EDT
Completed Phase 1 Interventional Results available

Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma

NCT02492750
View directory record Official record
Conditions
Indolent Plasma Cell Myeloma, Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
Interventions
Anakinra, Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide, Placebo
Biological · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Sep 25, 2026, 9:10 AM EDT
Recruiting Phase 2 Interventional

Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)

NCT06100237
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Teclistamab, Talquetamab, Daratumumab SC
Drug
Lead sponsor
Carl Ola Landgren, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 25, 2026, 9:10 AM EDT
Active, not recruiting Phase 2 Interventional

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

NCT05014646
View directory record Official record
Conditions
Smoldering Plasma Cell Myeloma
Interventions
Cholestyramine, Leflunomide
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Duarte, California • Detroit, Michigan • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 25, 2026, 9:10 AM EDT
Recruiting Phase 3 Interventional

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

NCT03937635
View directory record Official record
Conditions
Smoldering Plasma Cell Myeloma
Interventions
Daratumumab, Dexamethasone, Lenalidomide, Quality-of-Life Assessment, Questionnaire Administration
Biological · Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
742
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 490 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 25, 2026, 9:10 AM EDT
Withdrawn Phase 2 Interventional

Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma

NCT03952832
View directory record Official record
Conditions
Smoldering Plasma Cell Myeloma
Interventions
Leflunomide, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Sep 25, 2026, 9:10 AM EDT
Recruiting Phase 1 Interventional

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma

NCT06768489
View directory record Official record
Conditions
Multiple Myeloma, Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis
Interventions
JNJ-79635322, Daratumumab, Pomalidomide, Lenalidomide
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Denver, Colorado • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 25, 2026, 9:10 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma

NCT02903381
View directory record Official record
Conditions
Smoldering Multiple Myeloma
Interventions
Nivolumab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Sep 25, 2026, 9:10 AM EDT
Completed Phase 2 Interventional Results available

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

NCT01484275
View directory record Official record
Conditions
High-risk Smoldering Multiple Myeloma
Interventions
Siltuximab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
8
States / cities
Chicago, Illinois • Rockville, Maryland • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Sep 25, 2026, 9:10 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

NCT01169337
View directory record Official record
Conditions
Light Chain Deposition Disease, Smoldering Multiple Myeloma
Interventions
Clinical Observation, Lenalidomide, Quality-of-Life Assessment
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
601
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 390 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 25, 2026, 9:10 AM EDT
Active, not recruiting Phase 2 Interventional

CAR- PRISM (PRecision Intervention Smoldering Myeloma)

NCT05767359
View directory record Official record
Conditions
Multiple Myeloma, Smoldering Multiple Myeloma
Interventions
Ciltacabtagene Autoleucel, Cyclophosphamide, Fludarabine Phosphate
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2040
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 25, 2026, 9:10 AM EDT
Recruiting Phase 2 Interventional

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

NCT05469893
View directory record Official record
Conditions
High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma, Multiple Myeloma
Interventions
Teclistamab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Irene Ghobrial, MD
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
3
States / cities
Denver, Colorado • Boston, Massachusetts • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 25, 2026, 9:10 AM EDT
Completed Phase 2 Interventional Results available

E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

NCT02279394
View directory record Official record
Conditions
Smoldering Myeloma, Smoldering Multiple Myeloma
Interventions
Elotuzumab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
9
States / cities
Denver, Colorado • Hartford, Connecticut • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Sep 25, 2026, 9:10 AM EDT
Active, not recruiting Early Phase 1 Interventional

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma

NCT04370483
View directory record Official record
Conditions
Smoldering Plasma Cell Myeloma
Interventions
Leflunomide, Quality-of-Life Assessment
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Sep 25, 2026, 9:10 AM EDT
Recruiting No phase listed Observational

Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial

NCT06212323
View directory record Official record
Conditions
Smoldering Multiple Myeloma
Interventions
Patients with smoldering myeloma undergoing active surveillance with diffusion weighted whole body MRI.
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 25, 2026, 9:10 AM EDT
Active, not recruiting Phase 2 Interventional

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma

NCT04933539
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Dexamethasone, Carfilzomib, Daratumumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 25, 2026, 9:10 AM EDT
Completed Phase 1 Interventional

Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study

NCT02697383
View directory record Official record
Conditions
Multiple Myeloma, High Risk Smoldering Multiple Myeloma
Interventions
Ixazomib (MLN9708), Dexamethasone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated May 12, 2024 · Synced Sep 25, 2026, 9:10 AM EDT
Completed Phase 3 Interventional Results available

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

NCT03301220
View directory record Official record
Conditions
Smoldering Multiple Myeloma
Interventions
Daratumumab SC: daratumumab + rHuPH20
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
23
States / cities
Phoenix, Arizona • Whittier, California • Miami, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 25, 2026, 9:10 AM EDT